Senzime Annual Report 2019

PM Senzime Annual Report 2019

 

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                    

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com

Erik Bergman, CFO

Tel: +46 (0)73-258 81 59, e-post: erik.bergman@senzime.com



 

TO THE EDITORS

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Senzime. www.senzime.com